Esma Saada-Bouzid

University Institute Of The Face And Neck
Nice, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Journal: Cancer chemotherapy and pharmacology

Published: July 18, 2026

Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer: A Phase 1 Dose-Expansion Nonrandomized Clinical Trial.

Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer: A Phase 1 Dose-Expansion Nonrandomized Clinical Trial.

Journal: JAMA otolaryngology-- head & neck surgery

Published: January 29, 2026

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Journal: Cancer research communications

Published: January 14, 2026

The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Journal: Cancer chemotherapy and pharmacology

Published: January 12, 2026

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 16, 2025

Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 03, 2025

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

Journal: ESMO open

Published: June 06, 2025

Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database.

Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 21, 2025

Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: February 10, 2025

Toripalimab in combination with cisplatin and gemcitabine in recurrent or metastatic nasopharyngeal carcinomas (UCNT RM) in first-line treatment

Toripalimab in combination with cisplatin and gemcitabine in recurrent or metastatic nasopharyngeal carcinomas (UCNT RM) in first-line treatment

Journal: Bulletin du cancer

Published: December 23, 2024

A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

Journal: ESMO open

Published: December 23, 2024

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Journal: Journal for immunotherapy of cancer

Published: November 25, 2024

Showing 1-12 of 93

Last Updated: 09/26/2026